1. Home
  2. BSL vs ALXO Comparison

BSL vs ALXO Comparison

Compare BSL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

N/A

Current Price

$12.96

Market Cap

167.8M

Sector

Finance

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.03

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BSL
ALXO
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.8M
172.8M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
BSL
ALXO
Price
$12.96
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $4.60
AVG Volume (30 Days)
47.6K
★ 1.3M
Earning Date
01-01-0001
11-24-2026
Dividend Yield
★ 9.55%
N/A
EPS Growth
N/A
★ 26.36
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.45
$0.86
52 Week High
$13.99
$2.66

Technical Indicators

Market Signals
Indicator
BSL
ALXO
Relative Strength Index (RSI) 58.00 40.49
Support Level $12.87 $1.03
Resistance Level $13.03 $1.34
Average True Range (ATR) 0.07 0.14
MACD 0.02 0.00
Stochastic Oscillator 90.38 5.13

Price Performance

Historical Comparison
BSL
ALXO

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: